Posts

Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk

Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
arcticnovartis

  • Phase III V-MONO study met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C reduction1
  • Results add to growing body of evidence for Leqvio across the ASCVD continuum
  • Data will be shared with regulatory agencies and presented at an upcoming medical meeting
  • V-MONO is part of the 60,000-patient VictORION clinical trial program assessing Leqvio for primary and secondary ASCVD prevention
/by
Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration

Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration
weberfr8

/by
Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration

Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration
weberfr8

/by
Negative impact of the IRA on patient access to innovative treatments

Negative impact of the IRA on patient access to innovative treatments
angilma1

/by
Novartis statement on Maximum Fair Price for Entresto

Novartis statement on Maximum Fair Price for Entresto
angilma1

/by
Every number has a story – my journey to Novartis as a Refugee

Every number has a story – my journey to Novartis as a Refugee
tavasat1

/by
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Is Diversity, Equity and Inclusion (DEI) really that important?

Is Diversity, Equity and Inclusion (DEI) really that important?
mihai_novartis

/by
Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML 

Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML 
arcticnovartis

  • Priority Review based on ASC4FIRST Phase III study with Scemblix® data first to show significantly improved molecular response and a favorable safety and tolerability profile compared to standard of care therapies (imatinib and 2G TKIs)1 
  • Treatment options combining high efficacy with safety and tolerability represent a critical gap in care for long-term CML management1
/by
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben

Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR

/by